MEDICAL SERVICES

Departments

Languages

  • English

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis. Clin Cancer Res. 2021 Dec 14. View abstract
  2. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. J Pathol. 2021 12; 255(4):425-437. View abstract
  3. The Differential Diagnosis of Medullary-Based Renal Masses. Arch Pathol Lab Med. 2021 09 01; 145(9):1148-1170. View abstract
  4. Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer. Prostate. 2021 Nov; 81(15):1159-1171. View abstract
  5. Assessment of BCOR Internal Tandem Duplications in Pediatric Cancers by Targeted RNA Sequencing. J Mol Diagn. 2021 10; 23(10):1269-1278. View abstract
  6. Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. J Mol Diagn. 2020 09; 22(9):1162-1178. View abstract
  7. Use of Deep Learning to Develop and Analyze Computational Hematoxylin and Eosin Staining of Prostate Core Biopsy Images for Tumor Diagnosis. JAMA Netw Open. 2020 05 01; 3(5):e205111. View abstract
  8. INSM1 expression in a subset of thoracic malignancies and small round cell tumors: rare potential pitfalls for small cell carcinoma. Mod Pathol. 2020 08; 33(8):1571-1580. View abstract
  9. Delayed Relapse of Paracoccidioidomycosis in the Central Nervous System: A Case Report. Open Forum Infect Dis. 2020 Apr; 7(4):ofaa077. View abstract
  10. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111. View abstract
  11. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. View abstract
  12. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. Int J Cancer. 2019 12 15; 145(12):3453-3461. View abstract
  13. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 06 01; 7(6). View abstract
  14. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clin Cancer Res. 2018 08 15; 24(16):3908-3916. View abstract
  15. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. Am J Pathol. 2018 06; 188(6):1478-1485. View abstract
  16. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer. 2017 Nov 13; 17(1):759. View abstract
  17. AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun. 2017 07 26; 8(1):142. View abstract
  18. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clin Cancer Res. 2016 Sep 15; 22(18):4651-63. View abstract
  19. Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. Am J Clin Pathol. 2016 May; 145(5):696-702. View abstract
  20. A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML. Mol Diagn Ther. 2015 Dec; 19(6):409-17. View abstract
  21. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res. 2015 Dec 15; 21(24):5619-29. View abstract
  22. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015 Aug 11; 12(6):922-36. View abstract
  23. Diversity of miRNAs, siRNAs, and piRNAs across 25 Drosophila cell lines. Genome Res. 2014 Jul; 24(7):1236-50. View abstract